Poll

Charcot Neuroarthropathy: A Major Cause of Morbidity in Diabetes

What role do bisphosphonates play in the management of a Charcot joint? Is arthrodesis preferred to osteotomy? What's the most common complication of Charcot foot? Take this mini-quiz.

 

Charcot neuroarthropathy is a major cause of morbidity for patients with diabetes mellitus.

Which statement about this neuropathy is false?

A. Bisphosphonates may expedite conversion of an active Charcot foot to a more stable, chronic stage.
B. Bisphosphonates significantly minimize bone resorption in patients with Charcot foot.
C. For medial column or more severe deformities, arthrodesis procedures are preferred to osteotomies.
D. The most common complication of Charcot foot is infection secondary to plantar ulcerations.
Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Related Content
Dhruv Kazi, MD | Credit: PCSK9 Forum
November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity
October 30th 2024

10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity

Chelsie Derman
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
SGLT2i Outperforms DPP4i in Improving Hepatic Fibrosis Indices in T2D, MASLD| Image Credit: Markus Spiske/Unsplash
October 15th 2024

SGLT2i Outperforms DPP4i in Improving Hepatic Fibrosis Indices in MASLD

Connor Iapoce
HCPLive Endocrinology Month in Review September 2024 thumbnail
October 6th 2024

Endocrinology Month in Review: September 2024

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.